Quantcast
Last updated on April 17, 2014 at 7:47 EDT

Latest Chris Chapple Stories

2010-04-19 09:09:16

Professor Chapple presents results from Phase 2 study Treatment options for idiopathic OAB (IOAB) patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple (GB) and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk...